We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Fred Saad

Fred Saad MD, FRCS

Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospital Center (CHUM), Director, Prostate Cancer Research, Montreal Cancer Institute/CRCHUM, Montréal, Québec

Fred Saad MD FRCS, is Professor and Chief of Urology and Director of G-U Oncology at the University of Montreal Hospital Center (CHUM). He holds the Raymond Garneau Chair in Prostate Cancer Research and is Director of clinical research and the molecular oncology research laboratory in Prostate Cancer. He is an active member of CUA, AUA, ASCO, ESMO, AAGUS and has held several leadership positions such as is Past-President of the Canadian Urologic Association and Chair of the NCIC G-U Group and CUOG. Dr. Saad has played a leadership role and been a co-author on many of the practice changing clinical trials and publications in advanced prostate cancer over the last 20 years. He presently sits on 7 steering committees of ongoing international clinical trials and serves on several guideline committees. He is a member of several editorial boards, including Lancet Oncology, JAMA Oncology, Nature Urology, Genitourinary Cancer, CUAJ and Urology. He has published over 600 peer-reviewed articles and with an h-factor of 110 and over 55,000 citations he is listed as one of the world’s most cited clinician-scientists. Dr. Saad’s research interests include novel therapeutics in prostate cancer, molecular prognostic markers and mechanisms of progression. He has over 40 clinical and basic research projects ongoing and has received over 40 million dollars in research grants. His numerous awards include the lifetime achievement award from the CHUM Research Center, Lifetime Achievement Award from the Quebec Urologic Association and in 2018 was named a Knight of The National Order of Quebec, the highest honor given by the Quebec government.

Disclosures

Dr. Saad discloses the following: Consultant, honoraria, advisory board member and research funding (institution): Astellas, Bayer, Janssen, Sanofi.